Capricor Therapeutics, Inc. (CAPR)
After hours:
- GuruFocus.com
Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Unveiling key financial outcomes and strategic milestones, Capricor Therapeutics sets a robust path for 2024.
- Zacks
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Capricor (CAPR) delivered earnings and revenue surprises of -181.82% and 50.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA– –Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1– –Recent FDA Feedback Supports Requests for a Pre-BLA Meetin
